Soligenix Inc. Achieves Significant Milestone in Phase 2a Study for Behçet’s Disease Treatment

Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, has announced successful results from its Phase 2a proof of concept study for SGX945 (dusquetide) in treating Behçet’s Disease. The study met its primary objective by demonstrating biological efficacy, with SGX945 showing a 40% improvement in the primary ulcer endpoint compared to a historical placebo group from the apremilast (Otezla(R)) Phase 3 study. Notably, these results were achieved despite the treatment period being limited to four weeks.

Out of eight patients involved in the open-label trial, seven reported reductions in ulcer duration, number, and pain, with the benefits persisting throughout the follow-up period. Importantly, no treatment-related adverse events were reported, underscoring the potential safety profile of SGX945. Christopher J. Schaber, CEO of Soligenix, highlighted the significance of these findings, stating they support the advancement of SGX945, including its reformulation for home-based subcutaneous administration. This development is part of Soligenix's broader strategy to address unmet medical needs in Behçet’s Disease and other innate immune-related inflammatory conditions.

For more detailed information on the study and its implications, visit https://ibn.fm/FqcXf. Soligenix continues to focus on developing and commercializing treatments for rare diseases, with a pipeline that includes potential therapies for cutaneous T-cell lymphoma, psoriasis, and vaccines for ricin toxin, filoviruses, and COVID-19. The company's efforts in the Public Health Solutions segment are supported by government grants and contracts, aiming to address critical public health challenges.

This milestone in the development of SGX945 represents a hopeful advancement for patients suffering from Behçet’s Disease, a rare and often debilitating condition. The positive outcomes from the Phase 2a study not only demonstrate the potential of SGX945 as a treatment option but also reinforce Soligenix's commitment to addressing rare diseases with significant unmet needs. As the company moves forward with further development and potential commercialization efforts, the medical community and patients alike await the next steps with anticipation.